首页 | 本学科首页   官方微博 | 高级检索  
     


Development of separation technology for the removal of radium-223 from decayed thorium-227 in drug formulations. Material screening and method development
Authors:Janne Olsen Frenvik  Solveig Kristensen  Olav B Ryan
Affiliation:1. Bayer AS, Oslo, Norway;2. School of Pharmacy, University of Oslo, Oslo, Norway
Abstract:Targeted thorium conjugates are currently being investigated as a new class of alpha-radiopharmaceuticals. The natural decay of thorium-227 (227Th) results in the ingrowth of radium-223 (223Ra). Consideration must, therefore, be given to define acceptable limits of 223Ra in the drug product at the time of dose administration. By effective sequestration of 223Ra, we aim to improve the radiochemical purity and extend the effective user window of drug products containing 227Th. 223Ra is the first progeny of 227Th and the only one with a long half-life (days). We have, therefore, focused on the removal of this specific species since the progenies of 223Ra will have a very limited lifetime in the formulation once 223Ra is removed. In this study, we investigated a multitude of materials for their ability to reduce the 223Ra level by: (1) passive diffusion or (2) by cartridge filtration on gravity columns. In addition, we probe the compatibility of these materials in the presence of antibody trastuzumab to assess the level of protein binding and estimate the quenching of radiolysis by binding of radionuclides. A screening matrix of organic and inorganic materials was established, i.e. strontium and calcium alginate gel beads, distearoyl phosphatidylglycerol (DSPG) liposomes, ceramic hydroxyapatite, Zeolite UOP type 4A and cation exchange resins AG50W-X8 and SOURCE 30S. First, passive diffusional uptake of 223Ra by suspended materials present in the formulation was measured as a decrease in sample radioactivity after separation. Second, selected materials were packed on gravity columns in order to evaluate the efficiency of column separation versus diffusional adsorption. The retention of 223Ra and 227Th were characterized by measuring the radioactivity in the eluate and on the columns. Finally, the compatibility between trastuzumab, as a selected model antibody, and suspensions of the binding materials was analyzed during storage of the drug product in the presence of adsorbent. The formation of H2O2 was evaluated to measure the influence of radionuclide binding material on radiolysis in the formulation. All the materials bound 223Ra by passive diffusional uptake ranging from 31% to 95% with DSPG liposomes demonstrating superiority at 95% efficiency. All materials suitable for assessment by gravity column filtration bound 223Ra almost quantitatively (~100%) and with minimal variation (relative standard deviation <1%). The uptake was significantly higher compared to passive diffusional uptake. Alginate gel beads, ceramic hydroxyapatite and SOURCE 30S reduced the antibody concentration in solution to 40–50% while the Zeolite UOP type 4A, AG50W-X8 resin and DSPG liposomes showed?≤10% reduction of antibody concentration. Ceramic hydroxyapatite significantly reduced H2O2 formed by radionuclide initiated radiolysis.
Keywords:223Ra  227Th  alpha particle  cancer radioimmunotherapy
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号